Patents Examined by Richard Grant Peckham
  • Pyrazole derivatives
    Patent number: 11999718
    Abstract: The Present invention provides a novel pyrazole derivative compound represented by Chemical formula 1, a stereoisomer thereof, a solvate thereof, an isotopic variant thereof, a tautomer thereof, or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition comprising the same. (In the above, A, B and R, and the like are the same as defined in the description of the invention.
    Type: Grant
    Filed: January 6, 2023
    Date of Patent: June 4, 2024
    Assignee: APTABIO THERAPEUTICS INC.
    Inventors: Soo Jin Lee, Sung Hwan Moon, Sooho Ban, Eunsil Lee, Eun Jung Shin, Yoo-Kyung Goh
  • Preparation for 6-amino-1H-pyrazolo[3,4-d]pyrimidine-based JAK kinase inhibitor and application thereof
    Patent number: 11993603
    Abstract: A medicament with excellent JAK kinase (Janus Kinase) inhibitory activity can be used to prevent, treat and/or improve an autoimmune disease (e.g., psoriasis, rheumatoid arthritis, inflammatory bowel disease, Sjogren's syndrome, Behcet's disease, multiple sclerosis, systemic lupus erythematosus and the like). The present invention also provides a pharmaceutically acceptable composition containing the compound and a method for preparing these compounds.
    Type: Grant
    Filed: September 5, 2019
    Date of Patent: May 28, 2024
    Assignees: INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF MEDICAL SCIENCES & PEKING UNION MEDICAL COLLEGE, CHINA PARMACEUTICAL UNIVERSITY
    Inventors: Tiantai Zhang, Dayong Zhang, Chengjuan Chen, Yuan Yin, Runan Yu, Lei Shu
  • Lasofoxifene treatment of breast cancer
    Patent number: 11980597
    Abstract: The disclosure provides methods for treating estrogen receptor positive (ER+) cancer in women with an effective amount of lasofoxifene, a pharmaceutically acceptable salt thereof, or a prodrug thereof. The disclosure also includes the detection of the Estrogen Receptor 1 (ESR1) gene mutations that lead to endocrine resistance and treatment of endocrine resistant ER+ cancers.
    Type: Grant
    Filed: March 30, 2023
    Date of Patent: May 14, 2024
    Assignee: Duke University
    Inventors: Kaitlyn Andreano, Ching-yi Chang, Donald P. McDonnell, Stephanie L. Gaillard
  • 9-(2-hydroxyquinolin-3-yl)-10-(2-hydroxyethyl)-3,3,6,6-tetramethyl-3,4,6,7,9,10-hexahydroacridine1,8(2H,5H)-dione as an antimicrobial compound
    Patent number: 11970478
    Abstract: A 9-(2-hydroxyquinolin-3-yl)-10-(2-hydroxyethyl)-3,3,6,6-tetramethyl-3,4,6,7,9,10-hexahydroacridine1,8(2H,5H)-dione compound, its synthesis, and its use as an antimicrobial agent.
    Type: Grant
    Filed: November 16, 2023
    Date of Patent: April 30, 2024
    Assignee: KING FAISAL UNIVERSITY
    Inventors: Hany Mohamed Abd El-Lateef Ahmed, Mai Mostafa Khalaf Ali, Antar Ahmed Abdelhamid Ahmed, Amer A. Amer
  • LRRK2 inhibiting compounds and use thereof for treating neurodegenerative diseases
    Patent number: 11912678
    Abstract: The present invention relates to a series of compounds having a structural benzothiazole-benzamide core with capacity to inhibit the LRRK2 enzyme, due to which the invention also relates to the use of these compounds for treating neurodegenerative diseases in which this enzyme is involved, such as Parkinson's Disease or Alzheimer's Disease.
    Type: Grant
    Filed: August 8, 2019
    Date of Patent: February 27, 2024
    Assignee: CONSEJO SUPERIOR DE INVESTIGACIONES CIENTÍFICAS
    Inventors: Ana Martinez Gil, Carmen Gil Ayuso-Gontan, Josefa Zaldivar Diaz De Bonilla, Rocio Benitez Fernandez